Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Current Leases for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For Q4 2025, Current Leases fell 16.67% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 16.67%, while the annual FY2025 figure was $3.0 million, 16.67% down from the prior year.
  • Current Leases hit $3.0 million in Q4 2025 for Artiva Biotherapeutics, up from $75000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $3.6 million in Q4 2024 and bottomed at $75000.0 in Q3 2025.
  • Average Current Leases over 3 years is $2.2 million, with a median of $3.3 million recorded in 2025.
  • On a YoY basis, Current Leases climbed as much as 2948.28% in 2025 and fell as far as 36.97% in 2025.
  • Artiva Biotherapeutics' Current Leases stood at $3.6 million in 2023, then rose by 0.61% to $3.6 million in 2024, then decreased by 16.67% to $3.0 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $3.0 million, $75000.0, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.